Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4556 |
Name | lung large cell carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung large cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Fexagratinib | lung large cell carcinoma | sensitive | detail... |
FGFR1 positive | AZD8055 + Fexagratinib | lung large cell carcinoma | sensitive | detail... |
FGFR1 positive | Fexagratinib + Vistusertib | lung large cell carcinoma | sensitive | detail... |
FGFR1 positive | Fexagratinib + Sirolimus | lung large cell carcinoma | sensitive | detail... |
TP53 R175L | NSC319726 | lung large cell carcinoma | sensitive | detail... |
TP53 wild-type | NSC319726 | lung large cell carcinoma | resistant | detail... |
FGFR1 amp | ODM-203 | lung large cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02185690 | Phase I | Binimetinib + Carboplatin + Pemetrexed Disodium | A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | Completed | CAN | 0 |
NCT03591731 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) | Active, not recruiting | FRA | 0 |
NCT03976518 | Phase II | Atezolizumab | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) | Completed | ITA | 0 |
NCT04245514 | Phase II | Durvalumab | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | Recruiting | DEU | CHE | 0 |
NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Recruiting | USA | 0 |
NCT05198830 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + TRC102 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05680922 | Phase I | LB2102 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05860296 | Phase Ib/II | Pembrolizumab + SLC-391 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Recruiting | USA | CAN | 0 |
NCT05879978 | Phase Ib/II | BI 764532 + Ezabenlimab | A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Recruiting | FRA | DEU | BEL | 1 |
NCT06393816 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC) | Recruiting | FRA | 1 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |